Engimmune Therapeutics raises €15.2M Seed round

The proceeds will be used to further build Engimmune's pipeline, expand the research team in Switzerland, and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs. Also, to advance the preclinical development of its lead ENG-001 for melanoma and other solid cancers, further expand the research team in Switzerland, and strengthen the intellectual property.

Source: https://www.prnewswire.com/news-releases/engimmune-therapeutics-raises-chf-15-5-million-in-seed-financing-to-develop-novel-t-cell-receptor-therapeutics-301538350.html